BGI Genomics(SZ:300676) Shen Zhen Shang Bao·2025-09-01 03:28Core Insights - The article discusses the launch of the innovative Stereo-seq V2 technology, which addresses the challenges of analyzing formalin-fixed paraffin-embedded (FFPE) samples, enabling high-resolution real-time monitoring of gene activity in both human cells and invading microorganisms [1][2]. Group 1: Technology Overview - Stereo-seq V2 is described as a "universal key" that unlocks the potential of archived clinical samples, facilitating a shift from merely visualizing cells to understanding the interactions between cells and microorganisms in precision medicine [1][2]. - The technology overcomes significant challenges associated with FFPE samples, such as RNA degradation and molecular cross-linking, through an innovative "repair" process that captures previously overlooked genetic signals [3]. Group 2: Clinical Applications - The introduction of Stereo-seq V2 is seen as a milestone for spatial omics technology, with applications in precision oncology, where it can identify gene copy number variations related to patient prognosis and discover novel gene splice variants that contribute to drug resistance [4]. - In infectious disease contexts, the technology allows for the direct localization of pathogens in tissue samples and assessment of host immune responses, guiding targeted therapies [4]. - The technology also holds promise in antibody drug development by rapidly identifying and locating pathogen-specific neutralizing antibody clones, thus accelerating the drug screening process [4]. Group 3: Previous Achievements - Prior to Stereo-seq V2, the national key laboratory had released the Stereo-cell technology, which achieved breakthroughs in multi-modal integration and in situ dynamic capture, marking a significant advancement in single-cell sequencing capabilities [5].